Physician profile
Julia E Branco
NPI 1245669316
$3,487.30
in general payments reported to CMS, 2019-2025
35 companies · $965 in 2025
The $965 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $194 · 2022: $559 · 2023: $736 · 2024: $1,033 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,734.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $698.88 | 2022-2025 | |
| Novo Nordisk INC | $672.86 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $320.48 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Pfizer INC. | $264.64 | 2022-2025 | |
| Teleflex LLC | $154.00 | 2024 | Urolift |
| Janssen Pharmaceuticals, INC | $137.49 | 2022-2025 | Spravato, Xarelto |
| Glaxosmithkline, LLC. | $121.59 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.73 | 2023-2025 | Jardiance |
| Abbott Laboratories | $105.57 | 2022-2025 | Freestyle Libre 3 |
| Lundbeck LLC | $105.08 | 2023-2025 | Rexulti, Vyepti |
| Axsome Therapeutics, INC. | $97.64 | 2023-2025 | Auvelity |
| Amgen INC. | $75.06 | 2023-2025 | Repatha, Otezla, Otezla |
| Otsuka America Pharmaceutical, INC. | $69.87 | 2022-2023 | Rexulti |
| Exact Sciences Corporation | $60.04 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $47.06 | 2022-2024 | Dexcom G6 Transmitter |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $38.05 | 2022 | |
| Esperion Therapeutics, INC. | $36.96 | 2024-2025 | Nexletol |
| Seqirus USA INC | $35.99 | 2024 | Fluad, Flucelvax |
| Astrazeneca Pharmaceuticals LP | $27.43 | 2022-2024 | Airsupra |
| Nevro Corp. | $26.41 | 2023 | Senza |
| Radius Health, INC. | $26.06 | 2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $25.09 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.89 | 2022 | |
| Edwards Lifesciences Corporation | $23.72 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Daiichi Sankyo INC. | $23.21 | 2023 | Injectafer |
| Itamar Medical INC | $22.51 | 2025 | Watchpatone |
| Neos Therapeutics, LP | $21.49 | 2024 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $17.90 | 2025 | Jornay Pm |
| Tris Pharma INC | $16.31 | 2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $15.66 | 2023 | Trintellix |
| Almatica Pharma LLC | $14.69 | 2023 | Loreev Xr |
| Globus Medical, INC. | $14.10 | 2025 | Senza |
| Idorsia Pharmaceuticals US INC | $13.98 | 2023 | Quviviq |
| Corium, LLC | $13.69 | 2023 | Azstarys |
| Astellas Pharma US INC | $13.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Branco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.